1. An antibody that specifically binds to human TNFα, comprising: a. the light chain variable domain comprising the sequence of SEQ ID NO: 2 or SEQ ID NO: 14, and b. the variable domain of the heavy chain containing the sequence of SEQ ID NO: 5.2. The antibody of claim 1, wherein the variable domain of the light chain comprises the sequence of SEQ ID NO: 2.3. The antibody of claim 1, wherein the variable domain of the light chain comprises the sequence of SEQ ID NO: 14.4. The antibody of claim 1, further comprising a linker comprising the sequence of SEQ ID NO: 7.5. The antibody according to claim 1, which contains the sequence of SEQ ID NO: 10.6. The antibody according to claim 1, which contains the sequence of SEQ ID NO: 17.7. A pharmaceutical composition comprising a therapeutically effective amount of an antibody according to claim 1 and a pharmaceutically acceptable carrier. A method of treating a TNFα-mediated disease, comprising administering to the individual, if necessary, the pharmaceutical composition of claim 7.9. The method of claim 8, wherein the TNF-alpha-mediated disease is an eye disease selected from the group consisting of uveitis, Behcet's disease, retinitis, dry eyes, glaucoma, Sjogren's syndrome, diabetic neuropathy, scleritis, age-related macular degeneration and keratitis .10. The method of claim 8, wherein the pharmaceutical composition is administered using ophthalmic, intranasal, auricular, sublingual, transdermal, local, oral, nasal, rectal or parenteral administration. The method of claim 10, wherein the pharmaceutical composition is administered once or divided into a course of treatment in a total dose of 0.1 to 100 mg of the antibody. The method of claim 8, wherein the TNF-alpha-mediated disease is uveitis,1. Антитело, которое специфически связывается с TNFα человека, содержащее:a. вариабельный домен легкой цепи, содержащий последовательность SEQ ID NO:2 или SEQ ID NO:14, иb. вариабельный домен тяжелой цепи, содержащий последовательно
